Foi 1299 75

Document 75
PRODUCT INFORMATION
OxyContin® modified release tablets

(10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg)
NAME OF THE MEDICINE

Non-proprietary name: Oxycodone hydrochloride
Chemical name: 4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
hydrochloride
CAS No.: 124-90-3
Molecular formula (anhydrous form): C18H21NO4.HCl

Molecular weight (anhydrous form): 351.83
Molecular formula (monohydrate form): C18H21NO4.HCl.H20
Molecular weight (monohydrate form): 369.84
Structural formula (anhydrous form):
DESCRIPTION
Oxycodone hydrochloride is a white, crystalline, odourless powder readily soluble in water,
sparingly soluble in ethanol and nearly insoluble in ether.
OxyContin tablets are modified release tablets designed to provide delivery of oxycodone
over 12 hours.
OxyContin 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg1 and 80 mg tablets have been
reformulated, and comprise a matrix formulation with a hydrogelling property (i.e. particles or
whole tablets become highly viscous (gel-like) in water), intended to be crush-deterrent and to
reduce the rapid release of oxycodone upon accidental or intentional misuse. The tablets have
been heat-treated to increase the mechanical strength of the tablet.
The physical properties of the reformulated OxyContin tablets were examined following an
extensive battery of physical manipulations. Beyond demonstrating that the reformulated
OxyContin tablets are harder to crush than another controlled release oxycodone formulation,
testing over the range of the reformulated OxyContin tablets fragment sizes showed that some
of the controlled release properties were still retained. Hydrogelling properties continued to be
demonstrated.
OxyContin modified release tablets 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg PI
mfpoxycr11215 Supersedes PI mfpoxycr11015 Page 1 of 16
The inactive ingredients in the reformulated OxyContin 10 to 80 mg tablets are: polyethylene
oxide, butylated hydroxytoluene (BHT) and magnesium stearate. The tablets’ film coating
also contain: Opadry Y-5-18024-A White (US version) (ARPING No. 3548) (10mg), Opadry
complete film coating system 05B97512 Gray (ARPING No. 12507) (15mg), Opadry YS-1-
14518-A Pink (ARPING No. 3547) (20mg), Opadry complete film coating system YS-1-
16518-A Brown (ARPING No. 12505) (30mg), Opadry Yellow YS-1-12525-A (ARPING
No. 3550) (40mg), Opadry complete film coating system 15B25501 Red (ARPING No.
12506) (60mg) and Opadry Y-5-11167-A Green (ARPING No. 3549) (80mg).
1
OxyContin 60 mg tablets are not marketed in Australia.
PHARMACOLOGY
Actions
Oxycodone is a full opioid agonist with no antagonist properties whose principal therapeutic
action is analgesia. It has an affinity for kappa, mu and delta opiate receptors in the brain and
spinal cord. Oxycodone is similar to morphine in its action. Other pharmacological actions of
oxycodone are in the central nervous system (CNS: respiratory depression, antitussive,
anxiolytic, sedative and miosis), smooth muscle (constipation, reduction in gastric, biliary and
pancreatic secretions, spasm of sphincter of Oddi and transient elevations in serum amylase)
and cardiovascular system (release of histamine and/or peripheral vasodilatation, possibly
causing pruritus, flushing, red eyes, sweating and/or orthostatic hypotension).
Opioids may influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some changes

that can be seen include an increase in serum prolactin and decreases in plasma cortisol and
testosterone. Clinical symptoms may manifest from these hormonal changes.
Pharmacokinetics
Absorption
Compared with morphine, which has an absolute bioavailability of approximately 30%,
oxycodone has a high absolute bioavailability of up to 87% following oral administration.
The mean apparent half-life of OxyContin tablets is 6.5 hours and steady-state is achieved in
about one day.
Release of oxycodone from OxyContin tablets is independent of pH under physiological

conditions.
OxyContin tablets have an oral bioavailability comparable with immediate release oral
oxycodone, but achieve maximal plasma concentrations at about three hours compared with 1-
1.5 hours for immediate release oral oxycodone. Peak and trough concentrations of oxycodone
from OxyContin tablets 10 mg administered 12-hourly are similar to those achieved from
immediate release oxycodone 5 mg administered 6-hourly.
Dose proportionality has been established for the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg1
and 80mg tablet strengths for both peak plasma concentrations (Cmax) and extent of absorption
(AUC).
Recent fasted and fed studies for OxyContin 10, 40 and 80 mg tablets indicate that food has
no significant effect on the extent of absorption of oxycodone from OxyContin tablets.
Distribution
Following absorption, oxycodone is distributed throughout the entire body. Oxycodone has
been found in breast milk (see PRECAUTIONS, Use in lactation).
Metabolism and Elimination

Oxycodone has an elimination half-life of approximately three hours and is metabolised in the
liver to form noroxycodone, oxymorphone, noroxymorphone, 6 α and β oxycodol and
conjugated glucuronides. CYP3A4 and CYP2D6 are involved in the formation of noroxycodone
and oxymorphone, respectively (see INTERACTIONS WITH OTHER MEDICINES). The
contribution of these metabolites to the analgesic effect is insignificant.
1
INDICATIONS
The management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.
CONTRAINDICATIONS
Hypersensitivity to opioids or to any of the constituents of OxyContin tablets, acute respiratory
depression, cor pulmonale, cardiac arrhythmias, acute asthma or other obstructive airways
disease, suspected mechanical gastrointestinal obstruction (e.g. bowel obstruction, strictures) or
any diseases/conditions that affect bowel transit (e.g. ileus of any type), suspected surgical
abdomen, severe renal impairment (creatinine clearance < 10 mL/min), severe hepatic
impairment (refer to Special Risk Groups), delayed gastric emptying, acute alcoholism, brain
tumour, increased cerebrospinal or intracranial pressure, head injury (due to risk of raised
intracranial pressure), severe CNS depression, convulsive disorders, delirium tremens,
hypercarbia, concurrent administration of monoamine oxidase inhibitors or within two weeks
of discontinuation of their use. Not recommended for pre-operative use or for the first 24 hours
post-operatively. Pregnancy.
CLINICAL TRIALS
A double-blind, placebo-controlled, fixed-dose, parallel group, two-week study was
conducted in 133 patients with persistent, moderate to severe pain, who were judged as
having inadequate pain control with their current therapy. In this study, OxyContin 20 mg
tablets, but not 10 mg tablets, was statistically significant in pain reduction compared with
placebo (text from OxyContin US Prescribing Information dated April 2013).
PRECAUTIONS
The major risk of opioid excess is respiratory depression, including subclinical respiratory
depression. As with all opioids, a reduction in dosage may be advisable in hypothyroidism.
Use with caution in opioid-dependent patients and in patients with hypotension, hypovolaemia,
diseases of the biliary tract, pancreatitis, inflammatory bowel disorders, prostatic hypertrophy,
adrenocortical insufficiency (Addison’s disease), toxic psychosis, chronic pulmonary, renal or
hepatic disease, myxoedema and debilitated elderly or infirm patients. As with all opioid
preparations, patients who are to undergo cordotomy or other pain-relieving surgical procedures
should not receive OxyContin tablets for 24 hours before surgery. Pain in the immediate pre-
operative period, and any symptoms of opioid withdrawal, should be managed with short-acting
analgesic agents. If further treatment with OxyContin tablets is then indicated the dosage
should be adjusted to the new post-operative requirement.
Hyperalgesia that will not respond to a further dose increase of oxycodone may very rarely
occur, in particular at high doses. An oxycodone dose reduction or change in opioid may be
required.
As with all opioid preparations, OxyContin tablets should be used with caution following
abdominal surgery as opioids are known to impair intestinal motility and should not be used
until the physician is assured of normal bowel function. Should paralytic ileus be suspected or
occur during use, OxyContin tablets should be discontinued immediately.
Use caution when prescribing OxyContin tablets for patients who have any underlying GI
disorders that may predispose them to intestinal obstruction. Patients with underlying GI
disorders such as oesophageal cancer or colon cancer with a small gastrointestinal lumen are at
greater risk.
OxyContin tablets should not be taken by patients with difficulty in swallowing or who have
been diagnosed with narrowing of the oesophagus. If patients experience swallowing
difficulties (e.g. choking, gagging, discomfort, regurgitation, tablets stuck in the throat) after
taking OxyContin tablets, they should be advised to seek immediate medical attention.
Use in chronic, non-malignant pain

The use of OxyContin tablets for the treatment of chronic pain which is not due to malignancy
should be restricted to situations where:
 all other conservative non-pharmacological and pharmacological methods of analgesia

have been tried and have failed or are insufficient
 the pain is having a significant impact on the patient’s quality of life
 there is no psychological contraindication, drug-seeking behaviour or past and current
personal or family history of alcohol, prescription/illicit drug abuse or misuse.
Opioids, where clinically indicated, should only be prescribed as one component of a

comprehensive multimodal management approach to chronic, non-malignant pain.
Appropriate patient selection is the key to successful treatment of moderate to severe chronic
pain with opioid analgesics.
An initial comprehensive assessment should be conducted using a biopsychosocial approach

to identify a cause for the pain and the appropriateness of opioid therapy - and to identify
psychosocial factors that may exacerbate pain or magnify overall distress (e.g. depression,
anxiety, post-traumatic stress disorder, borderline personality disorder, marked family
stressors, history of sexual abuse). In the absence of a clear indication for a strong opioid
analgesic, drug-seeking behaviour must be suspected and resisted, particularly in individuals
with a history of, or propensity for, drug abuse. Factors that may put the patient at increased
risk of opioid abuse/addiction include a personal/family history of substance, prescription
medication and alcohol abuse, and major psychosocial issues (e.g. psychological/psychiatric
disorder). The use of opioids to treat predominant emotional distress should be avoided.
Generally, opioid analgesics are not initiated prior to a full initial clinical assessment and
before consideration of other treatment options such as physiotherapy/exercise/rehabilitation
approaches, psychosocial interventions such as CBT (cognitive-behavioural therapy) self-
management approaches, involvement of a psychologist or psychiatrist to address
psychological co-morbidities which may be impacting on pain coping and trials of other non-
opioid pharmacotherapeutic or interventional strategies.
Prior to longer-term prescribing, a trial of OxyContin tablets or shorter-acting opioid should

be undertaken. Longer-term administration of OxyContin tablets should only occur if this
trial demonstrates that the pain is opioid sensitive. Opioid-naïve patients who require rapid
dose escalation with no concomitant pain relief within the trial period should generally be
considered inappropriate for longer-term therapy.
One doctor only should be responsible for the prescription and monitoring of the patient’s
opioid use. Prescribers should consult appropriate clinical guidelines on the use of opioid
analgesics in such patients (e.g. those published by the Australian Pain Society in the Medical
Journal of Australia 1997; 167: 30-4).
Drug dependence
As with other opioids, tolerance and physical dependence tend to develop upon repeated
administration of oxycodone. There is potential for abuse of the drug and for development of
strong psychological dependence. OxyContin tablets should therefore be prescribed and
handled with a high degree of caution appropriate to the use of a drug with strong abuse
potential.
Withdrawal symptoms may occur following abrupt discontinuation of oxycodone therapy or

upon administration of an opioid antagonist. Therefore, patients on prolonged therapy should
be withdrawn gradually from the drug if it is no longer required for pain control.
Oxycodone should be used with caution and under close supervision in patients with pain not
due to malignancy who have a prior history of substance abuse. In such cases, prior
psychological assessment is essential and the prescribing doctor should consider whether the
benefit of treatment outweighs the risk of abuse.
Drug abuse studies

Intranasal abuse
In a human abuse liability study, milled OxyContin 30 mg tablets produced subjective
responses on each of the four established primary measures that were greater than placebo but
significantly less than the responses for another, conventional finely crushed controlled release
oxycodone tablets formulation 30 mg, or a fine powder of oxycodone 30 mg when administered
intranasally in healthy recreational opioid users with a history of intranasal drug abuse/misuse
(n=27). The primary measures were: ‘Drug-liking ‘at this moment’’; ‘Overall drug liking’;
‘Subjective Drug Value’; ‘Addiction Research Centre Inventory (ARCI) Morphine Benzedrine
Group (MBG)’ scales.
Objective measures of pupil diameter and other subjective measures were consistent with a
lower opioid effect. Measurements of intranasal irritation showed increased irritation,
particularly related to nasal stuffiness, with OxyContin tablets compared with another
conventional controlled release oxycodone tablets formulation or oxycodone powder.
In a tolerability and safety study with healthy subjects under fasting conditions, milled
OxyContin tablets were shown to cause increased nasal discomfort, particularly related to
increased nasal stuffiness, and a decrease in runny nose scores when compared with another
finely milled controlled release oxycodone tablets formulation, when administered intranasally.
Although total AUC was similar for all treatments, Cmax was 67% for coarsely and 77.6% for
finely milled OxyContin tablets (Ratio of metric means expressed as a percent, transformed
back to the linear scale) compared with the other finely milled conventional controlled release
oxycodone tablets formulation and Tmax was later with OxyContin tablets.
An additional study was conducted to assess the administration site safety and tolerability of
intranasally administered milled OxyContin tablets placebo vs another crushed conventional
controlled release oxycodone tablets formulation placebo. Endoscopy photographs showed
residual particles in the nasal cavity at 30 minutes following administration of OxyContin
tablets placebo.
Accidental or Intentional Oral Misuse

A study in healthy subjects was conducted to characterize the impact of chewing intact and
tampered tablets and subsequent swallowing, on the pharmacokinetics of OxyContin tablets
under fasting conditions. The manufacturing process for OxyContin tablets imparts increased
hardness to the tablets. Subjects were required to complete a chewing qualification assessment
prior to receiving their initial study doses.
The results showed that under both normal and vigorous chewing conditions, OxyContin
tablets retained some of their controlled release characteristics. Peak plasma levels of
oxycodone (Cmax) for OxyContin tablets were 13.5% lower when swallowed after vigorous
chewing and 23.6% lower when swallowed after normal chewing (Ratio of metric means
expressed as a percent, transformed back to the linear scale) when compared with another
chewed conventional formulation of controlled release oxycodone tablets. The time to reach
peak plasma levels (Tmax) was also delayed for OxyContin tablets compared with the other
conventional controlled release oxycodone tablet formulation, under both vigorous (1.5 vs 1.0
hours respectively) and normal (2.38 vs 1.13 hours respectively) chewing conditions.
Formulation
OxyContin tablets are intended for oral use only. The modified release tablets must be
swallowed whole, and not broken, chewed or crushed. The administration of broken, chewed
or crushed modified release oxycodone tablets leads to a rapid release and absorption of a
potentially fatal dose of oxycodone. Parenteral venous injection of the tablet constituents can
be expected to result in local tissue necrosis, pulmonary granulomas and serious adverse
reactions which may be fatal.
Effects on fertility
In reproductive toxicology studies, no evidence of impaired fertility was seen in male or
female rats at oral oxycodone doses of 8 mg/kg/day, with estimated exposure (plasma AUC)
equivalent to 8 mg/day in men and 17 mg/day in women.
Despite these fertility studies in animals, prolonged use of opioids may result in impairment
of reproductive function, including fertility and sexual dysfunction in both sexes, and
irregular menses in women.
Use in pregnancy
Australian Pregnancy Category C: Drugs which, owing to their pharmacological effects, have
caused or may be suspected of causing, harmful effects on the human fetus or neonate without
causing malformations. These effects may be reversible.
Oxycodone used during pregnancy or labour may cause withdrawal symptoms and/or
respiratory depression in the newborn infant. Oral administration of oxycodone during the
period of organogenesis did not elicit teratogenicity or embryofetal toxicity in rats or rabbits at
doses up to 8 mg/kg/day in rats (equivalent to 17 mg/day in women, based on estimated plasma
AUC values) or 125 mg/kg/day in rabbits.
Oral administration of oxycodone to rats from early gestation to weaning did not affect
postnatal development parameters at doses up to 6 mg/kg/day (equivalent to 9 mg/day in
women, based on estimated AUC values). In a study designed specifically to investigate the
effect of pre-natal oxycodone on the hypothalamic-pituitary-adrenal axis in adolescent rats,
intravenous administration of oxycodone 0.8 mg/kg/day (equivalent to 11 mg/day in pregnant
women, based on estimated AUC values) had no effect on the corticosterone response, but
delayed and enhanced the peak ACTH response to corticotrophin releasing hormone in males,
but not females. The clinical significance of this observation is unknown.
There are no adequate and well-controlled studies with oxycodone in pregnant women.
Because animal reproduction studies are not always predictive of human responses, oxycodone
should not be used during pregnancy unless clearly needed. Prolonged use of oxycodone during
pregnancy can result in neonatal opioid withdrawal. Oxycodone is not recommended for use in
women during or immediately prior to labour. Infants born to mothers who have received
opioids during pregnancy should be monitored for respiratory depression.
Use in lactation
Oxycodone accumulates in human milk, with a median maternal milk:plasma ratio of 3:1
recorded in one study. Oxycodone (7.5 ng/mL) was detected in the plasma of one of forty-
one infants 72 hours after Caesarean section. Opioids may cause respiratory depression in the
newborn and withdrawal symptoms can occur in breastfeeding infants when maternal
administration of an opioid analgesic is stopped. OxyContin tablets should not be used in
breastfeeding mothers unless the benefits outweigh the risks. Breastfed infants should be
monitored for respiratory depression, sedation, poor attachment and gastrointestinal signs.
Special Risk Groups

Use in renal and hepatic impairment
In renal and hepatic impairment, the administration of OxyContin tablets does not result in
significant levels of active metabolites. However, the plasma concentration of oxycodone in
this patient population may be increased compared with patients having normal renal or hepatic
function. Therefore, initiation of dosing in patients with renal impairment (CrCl< 60 mL/min)
or hepatic impairment should be reduced to ⅓ to ½ of the usual dose with cautious titration.
Use in the elderly

The plasma concentrations of oxycodone are only nominally affected by age, being
approximately 15% greater in elderly as compared with young subjects. There were no
differences in adverse event reporting between young and elderly subjects.
Use in elderly, debilitated patients
As with other opioid initiation and titration, doses in elderly patients who are debilitated should
be reduced to ⅓ to ½ of the usual doses.
Gender
Female subjects have, on average, plasma oxycodone concentrations up to 25% higher than
males on a body weight adjusted basis. The reason for this difference is unknown. There were
no significant male/female differences detected for efficacy or adverse events in clinical trials.
Genotoxicity
Oxycodone was not genotoxic in bacterial gene mutation assays but was positive in the mouse
lymphoma assay. In assays of chromosomal damage, genotoxic effects occurred in the human
lymphocyte chromosomal aberration assay in vitro, but not in the in vivo bone marrow
micronucleus assay in mice.
Carcinogenicity
Studies of oxycodone in animals to evaluate its carcinogenic potential have not been
conducted.
Driving and operating dangerous machinery

Oxycodone may modify patients’ reactions to a varying extent depending on the dosage and
individual susceptibility. If their ability is impaired, patients should not drive or operate
machinery.
INTERACTIONS WITH OTHER MEDICINES

Anticholinergic agents
Concurrent use with oxycodone with anticholinergics or medications with anticholinergic
activity (e.g. tricyclic antidepressants, antihistamines, antipsychotics, muscle relaxants, anti-
Parkinson medications) may result in increased anticholinergic adverse effects, including an
increased risk of severe constipation and/or urinary retention.
Antihypertensive agents
Hypotensive effects of these medications may be potentiated when used concurrently with
oxycodone, leading to increased risk of orthostatic hypotension.
CNS depressants (including sedatives or hypnotics, general anaesthetics, phenothiazines, other

tranquillisers, alcohol, other opioids and neuroleptic drugs, etc.)
Concurrent use with oxycodone may result in increased respiratory depression, hypotension,
profound sedation or coma. Caution is recommended and the dosage of one or both agents
should be reduced. Intake of alcoholic beverages while being treated with OxyContin tablets
should be avoided because this may lead to more frequent undesirable effects such as
somnolence and respiratory depression. Oxycodone hydrochloride containing products
should be avoided in patients with a history of or present alcohol, drug or medicines abuse.
Coumarin derivatives
Although there is little substantiating evidence, opiate agonists have been reported to potentiate
the anticoagulant activity of coumarin derivatives.
CYP2D6 and CYP3A4 inhibitors and inducers
Oxycodone is metabolised in part via the CYP2D6 and CYP3A4 pathways. The activities of
these metabolic pathways may be inhibited or induced by various co-administered drugs or
dietary elements, which may alter plasma oxycodone concentrations. Oxycodone doses may
need to be adjusted accordingly. Drugs that inhibit CYP2D6 activity, such as paroxetine and
quinidine, may cause decreased clearance of oxycodone which could lead to an increase in
oxycodone plasma concentrations. Concurrent administration of quinidine does not alter the
pharmacodynamic effects of oxycodone. CYP3A4 inhibitors such as macrolide antibiotics (e.g.
clarithromycin), azole antifungal agents (e.g. ketoconazole), protease inhibitors (e.g. ritonavir)
and grapefruit juice may cause decreased clearance of oxycodone which could lead to an
increase in oxycodone plasma concentrations. Oxycodone metabolism may be blocked by a
variety of drugs (e.g. cimetidine, certain cardiovascular drugs and antidepressants), although
such blockade has not yet been shown to be of clinical significance with OxyContin tablets.
CYP3A4 inducers, such as rifampin, carbamazepine, phenytoin and St. John's wort, may induce
the metabolism of oxycodone and cause increased clearance of the drug, resulting in a decrease
in oxycodone plasma concentrations.
Oxycodone did not inhibit the activity of P450 isozymes 2D6, 3A4, 1A2, 2A6, 2C19 or 2E1 in
human liver microsomes in vitro. Non-clinical data in vitro and in vivo indicate that oxycodone
can act as a P-glycoprotein substrate and can induce overexpression of P-glycoprotein in rats.
Metoclopramide
Concurrent use with oxycodone may antagonise the effects of metoclopramide on
gastrointestinal motility.
Monoamine Oxidase Inhibitors (MAOIs)

Non-selective MAOIs intensify the effects of opioid drugs which can cause anxiety, confusion
and significant respiratory depression. Severe and sometimes fatal reactions have occurred in
patients concurrently administered MAOIs and pethidine. Oxycodone should not be given to
patients taking non-selective MAOIs or within 14 days of stopping such treatment. As it is
unknown whether there is an interaction between selective MAOIs (e.g. selegiline) and
oxycodone, caution is advised with this drug combination.
Neuromuscular blocking agents

Oxycodone may enhance the effects of neuromuscular blocking agents resulting in increased
respiratory depression.
Opioid agonist analgesics (including morphine, pethidine)

Additive CNS depressant, respiratory depressant and hypotensive effects may occur if two or
more opioid agonist analgesics are used concurrently.
Opioid agonist-antagonist analgesics (including pentazocine, butorphanol, buprenorphine)

Mixed agonist/antagonist analgesics may reduce the analgesic effect of oxycodone and/or may
precipitate withdrawal symptoms.
ADVERSE EFFECTS
Adverse drug reactions are typical of full opioid agonists, and tend to reduce with time, with the
exception of constipation. Anticipation of adverse drug reactions and appropriate patient
management can improve acceptability.
Cardiac disorders
Uncommon bradycardia, chest pain, palpitations (as part of withdrawal syndrome), ST
depression, supraventricular tachycardia
Ear and labyrinth disorders

Uncommon tinnitus, vertigo
Eye disorders
Uncommon miosis, visual impairment
Gastrointestinal disorders
Very common nausea, vomiting, constipation
Common abdominal pain, diarrhoea, dry mouth, dyspepsia, gastritis, hiccup
Uncommon colic, dental caries, dysphagia, eructation, flatulence, gastrointestinal disorder,
ileus, stomatitis, regurgitation, retching
General disorders and administration site conditions

Common asthenia, fatigue, chills, fever
Uncommon accidental injury, drug tolerance, drug withdrawal syndrome (with or without
seizures), facial flushing, lymphadenopathy, malaise, muscular rigidity, neck
pain, oedema, peripheral oedema, pain, thirst
Not known drug withdrawal syndrome neonatal
Hepatobiliary disorders
Uncommon biliary spasm, cholestasis, hepatic enzyme increased
Immune system disorders

Uncommon allergic reaction, anaphylactic reaction, anaphylactoid reaction,
hypersensitivity
Injury, poisoning and procedural complications

Uncommon medication struck in throat
Metabolism and nutrition disorders

Common decreased appetite
Uncommon increased appetite, dehydration, hyponatraemia
Nervous system disorders

Very common dizziness, headache, somnolence
Common faintness, sedation, twitching, tremor, lethargy
Uncommon amnesia, drowsiness, abnormal gait, convulsion, dysgeusia (taste perversion),
hyperkinesia, hypertonia, hypoaesthesia, hypothermia, raised intracranial
pressure, muscle contractions involuntary, paraesthesia, seizures, speech
disorder, stupor, syncope
Not Known hyperalgesia
Psychiatric disorders
Common abnormal dreams, anxiety, confusional state, insomnia, nervousness, thinking
abnormal, depression
Uncommon affect lability, agitation, disorientation, drug dependence, dysphoria, euphoric
mood, hallucination, libido decreased, mood altered, restlessness
Not known aggression
Renal and urinary disorders

Uncommon ureteric spasm, urinary abnormalities, urinary retention, urinary tract infection
Reproductive system and breast disorders

Uncommon amenorrhoea, erectile dysfunction, hypogonadism
Respiratory, thoracic and mediastinal disorders

Common bronchospasm, dyspnoea, pharyngitis, voice alteration
Uncommon respiratory depression, choking
Skin and subcutaneous tissue disorders

Very common pruritus
Common hyperhidrosis, rash
Uncommon dry skin, exfoliative dermatitis, urticaria and other skin rashes
Vascular disorders
Common orthostatic hypotension
Uncommon hypotension, migraine, vasodilatation
Key: Very common (≥ 1/10)

Common (≥ 1/100 to < 1/10)
Uncommon (≥ 1/1000 to < 1/100)
Rare (≥ 1/10,000 to < 1/1000)
Very rare (< 1/10,000)
Not known (cannot be estimated from the available data)
If nausea and vomiting are troublesome, oxycodone may be combined with an antiemetic.
Constipation must be treated with appropriate laxatives. Overdose may produce respiratory
depression. Compared with other opioids, oxycodone is associated with low histamine release
although urticaria and pruritus may occur.
Post-marketing
There have been rare post-marketing cases of intestinal obstruction, and exacerbation of
diverticulitis, some of which have required medical intervention to remove the tablet.
There have been uncommon post-marketing reports of difficulty swallowing OxyContin 10 mg

to 80 mg tablets, potentially due to the swelling and hydrogelling property of the tablets:
choking, gagging, regurgitation, tablets stuck in the throat and difficulty swallowing the tablet.
DOSAGE AND ADMINISTRATION
OxyContin tablets 60 mg1 and 80 mg should only be used in opioid-tolerant patients.
These tablet strengths may cause fatal respiratory depression in patients not previously
exposed to opioids (opioid naïve).
OxyContin tablets are to be swallowed whole, and are not to be cut, broken, chewed,
crushed or dissolved. The tablets have been hardened to reduce the risk of being
accidently or intentionally broken, chewed or crushed. Taking cut, broken, chewed,
crushed or dissolved OxyContin tablets could lead to the rapid release and absorption of a
potentially fatal dose of oxycodone.
To avoid difficulty swallowing, OxyContin tablets should not be pre-soaked, licked or

otherwise wetted prior to placing in the mouth and should be taken one tablet at a time with
enough water to ensure complete swallowing immediately after placing it in the mouth.
There are no data on rectal administration of OxyContin tablets, therefore rectal administration
of OxyContin tablets is not recommended.
Do not administer OxyContin tablets via nasogastric, gastric or other feeding tubes as it may
cause obstruction of feeding tubes.
Alcoholic beverages should be avoided by patients while being treated with OxyContin tablets.
1
Adults, elderly and children over 12 years

Prior to initiation and titration of doses, refer to the PRECAUTIONS section for information
on special risk groups such as females and the elderly. OxyContin tablets should be taken at 12-
hourly intervals. Appropriate pain management principles of careful assessment and ongoing
monitoring should be followed at regular intervals, including reassessing the need for continued
opioid therapy. The dosage is dependent on the severity of the pain, and the patient’s previous
history of analgesic requirements.
The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe
pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives,
muscle relaxants or other CNS medicines) is 10 mg 12-hourly.
The dose should then be carefully titrated with longitudinal patient monitoring, assessing
whether the pain is opioid responsive and providing the patient significant pain relief.
Increasing severity of pain may require an increased dosage of OxyContin tablets to achieve a
stable dose that provides acceptable pain relief. The correct dosage for any individual patient is
that which controls the pain and is well tolerated, for a full 12 hours. If higher doses are
necessary, increases should be made, where possible, in 25% - 50% increments.
Patients who experience breakthrough pain may require dosage adjustment or rescue
medication. The need for rescue medication more than twice a day indicates that the patient
should be reassessed and, only if appropriate, the dosage of OxyContin tablets should be
increased. There are no well-controlled clinical studies evaluating the safety and efficacy with
dosing more frequently than every 12 hours.
Patients receiving oral morphine before OxyContin tablet therapy should have their daily dose
based on the following ratio: 10 mg of oral oxycodone is equivalent to 20 mg of oral morphine.
It is emphasised that this is a guide to the dose of OxyContin tablets required only. Inter-patient
variability requires that each patient is carefully titrated to the appropriate dose.
Controlled pharmacokinetic studies in elderly patients (aged over 65 years) have shown that
compared with younger adults the clearance of oxycodone is only slightly reduced. No
untoward adverse drug reactions were seen based on age, therefore adult doses and dosage
intervals are appropriate.
Children under 12 years

OxyContin tablets are not recommended for children under 12 years of age.
Patients with renal or hepatic impairment

The dose initiation should follow a conservative approach in these patients. The recommended
adult starting dose should be reduced by ⅓ to ½, and each patient should be titrated to adequate
pain control according to their clinical situation (see PRECAUTIONS, Special Risk Groups).
Patients transferring from other opioid formulations

Patients receiving other oral oxycodone formulations may be transferred to OxyContin tablets at
the same total daily dosage, equally divided into two 12-hourly OxyContin tablet doses. For
patients who are receiving an alternative opioid, the “oral oxycodone equivalent” of the
analgesic presently being used should be determined. Having determined the total daily dosage
of the present analgesic, the following equivalence table can be used to calculate the
approximate daily oral oxycodone dosage that should provide equivalent analgesia. The total
daily oral oxycodone dosage should then be equally divided into two 12-hourly OxyContin
tablet doses.
Multiplication Factors for Converting the Daily Dose

of Prior Opioids to the Daily Dose of Oral Oxycodone*
(mg/Day Prior Opioid x Factor = mg/Day Oral Oxycodone)
Oral Prior Opioid Parenteral Opioid

Oxycodone 1 --
Codeine 0.15 --
Fentanyl TTS SEE BELOW** SEE BELOW**
Hydromorphone 4 20
Pethidine 0.1 0.4
Methadone 1.5 3
Morphine 0.5 3
* To be used for conversion to oral oxycodone. For patients receiving high-dose parenteral
opioids, a more conservative conversion is warranted. For example, for high-dose parenteral morphine,
use 1.5 instead of 3 as a multiplication factor.
** Conversion from transdermal fentanyl to OxyContin tablets: 18 hours following the removal of
the transdermal fentanyl patch, OxyContin tablets treatment can be initiated. Although there has been no
systematic assessment of such conversion, a conservative oxycodone dose, approximately 10 mg 12-
hourly of OxyContin tablets, should be initially substituted for each 25 µg/hr fentanyl transdermal patch.
The patient should be followed closely.
OVERDOSAGE
Symptoms
Acute overdosage with oxycodone can be manifested by respiratory depression (reduced
respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme
somnolence progressing to stupor or coma, hypotonia, cold and/or clammy skin, miosis
(dilated if hypoxia is severe), and sometimes bradycardia, hypotension, and death. Severe
overdose may result in apnoea, pulmonary oedema, circulatory collapse and death. The
features of overdose may be delayed with a sustained release product such as OxyContin
tablets.
Treatment of oxycodone overdosage

Primary attention should be given to immediate supportive therapy with the establishment of
adequate respiratory exchange through the provision of a patent airway and institution of
assisted or controlled ventilation. Adequate body temperature and fluid balance should be
maintained. Oxygen, intravenous fluids, vasopressors and other supportive measures should
be used as indicated, to manage the circulatory shock accompanying an overdose. Cardiac
arrest or arrhythmias may require cardiac massage or defibrillation.
Activated charcoal may reduce absorption of the drug if given within one to two hours after
ingestion. Administration of activated charcoal should be restricted to patients who are fully
conscious with an intact gag reflex or protected airway. A saline cathartic or sorbitol added to
the first dose of activated charcoal may speed gastrointestinal passage of the product. In
patients who are not fully conscious or have an impaired gag reflex, consideration should be
given to administering activated charcoal via a nasogastric tube, once the airway is protected.
Whole bowel irrigation (e.g. 1 or 2 litres of polyethylene glycol solution orally per hour until
rectal effluent is clear) may be useful for gut decontamination. Whole bowel irrigation is
contraindicated in patients with bowel obstruction, perforation, ileus, haemodynamic
instability or compromised, unprotected airways and should be used cautiously in debilitated
patients and where the condition may be further compromised. Concurrent administration of
activated charcoal and whole bowel irrigation may decrease the effectiveness of the charcoal
(there may be competition for the charcoal binding site between the polyethylene glycol and
the ingested drugs) but the clinical relevance is uncertain. Prolonged periods of observation
(days) may be required for patients who have overdosed with long-acting oxycodone
preparations.
If there are signs of clinically significant respiratory or cardiovascular depression, the use of
an opioid antagonist should be considered. The opioid antagonist naloxone hydrochloride is a
specific antidote for respiratory depression due to overdosage or as a result of unusual
sensitivity to opioid. The usual intravenous adult dose of naloxone is 0.4 mg or higher (please
refer to naloxone product information for further information). The onset of naloxone effect
may be delayed by 30 minutes or more. Concomitant efforts at respiratory resuscitation
should be carried out. Since the duration of action of oxycodone, particularly sustained
release formulations, may exceed that of the antagonist, the patient should be under continued
surveillance and doses of the antagonist should be repeated as needed, or an antagonist
infusion established, to maintain adequate respiration.
In an individual physically dependent on, or tolerant to, opioids, the administration of the
usual dose of opioid antagonist can precipitate an acute withdrawal syndrome. This may lead
to agitation, hypertension, tachycardia and risk of vomiting with possible aspiration. The
severity of this syndrome will depend on the degree of physical dependence and the dose of
antagonist administered. The use of opioid antagonists in such individuals should be avoided
if possible. If an opioid antagonist must be used to treat serious respiratory depression in the
physically dependent patient, the antagonist should be administered with extreme care by
using dosage titration, commencing with 10 to 20% of the usual recommended initial dose.
Toxicity
Oxycodone toxicity may result from overdosage but because of the great interindividual
variation in sensitivity to opioids it is difficult to determine an exact dose of any opioid that is
toxic or lethal. Crushing and taking the contents of a modified release dosage form leads to
the release of oxycodone in an immediate fashion; this might result in a fatal overdose. The
toxic effects and signs of overdosage may be less pronounced than expected, when pain
and/or tolerance are manifest.
Please phone the Poisons Information Centre on 13 11 26 for advice on managing overdose.
PRESENTATION AND STORAGE CONDITIONS

Presentation
OxyContin® modified release tablets are round, unscored bi-convex tablets embossed with
letters and numerals and contain the following quantities of oxycodone hydrochloride:
OxyContin® 10 mg contains oxycodone hydrochloride 10 mg (white, embossed with OP on one
side and 10 on the other)
OxyContin® 15 mg contains oxycodone hydrochloride 15 mg (grey, embossed with OP on one
OxyContin® 20 mg contains oxycodone hydrochloride 20 mg (pink, embossed with OP on one
OxyContin® 30 mg contains oxycodone hydrochloride 30 mg (brown, embossed with OP on
one side and 30 on the other)
OxyContin® 40 mg contains oxycodone hydrochloride 40 mg (yellow, embossed with OP on
one side and 40 on the other)
OxyContin® 60 mg contains oxycodone hydrochloride 60 mg (red, embossed with OP on one
OxyContin® 80 mg contains oxycodone hydrochloride 80 mg (green, embossed with OP on one
Strengths and Pack sizes available in Australia:

10 mg – 28 tablets in blister packs
Strengths and Pack sizes not available in Australia:

10 mg – 20 tablets in blister packs and 10, 28, 100 and 120 tablets in bottles
60 mg – 20 and 28 tablets in blister packs and 10, 28, 100 and 120 tablets in bottles
Storage Conditions
Store below 25ºC.
NAME AND ADDRESS OF THE SPONSOR

Mundipharma Pty Limited
ABN 87 081 322 509
88 Phillip Street
SYDNEY, NSW 2000
Further information may be obtained from Mundipharma’s Medical Information Department

1800 188 009
POISON SCHEDULE OF THE MEDICINE

S8
DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC

GOODS (the ARTG)
OxyContin® tablets 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg: 22 October 2013
DATE OF MOST RECENT AMENDMENT

23 December 2015
® OXYCONTIN is a registered trademark.
Orbis RA-3069

Foi 1299 75

Uploaded by

Copyright:

Available Formats

Foi 1299 75

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Foi 1299 75

Uploaded by

Copyright:

Available Formats

Document 75

OxyContin® modified release tablets

NAME OF THE MEDICINE

Molecular formula (anhydrous form): C18H21NO4.HCl

Opioids may influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some changes

Release of oxycodone from OxyContin tablets is independent of pH under physiological

Metabolism and Elimination

Use in chronic, non-malignant pain

 all other conservative non-pharmacological and pharmacological methods of analgesia

Opioids, where clinically indicated, should only be prescribed as one component of a

An initial comprehensive assessment should be conducted using a biopsychosocial approach

Prior to longer-term prescribing, a trial of OxyContin tablets or shorter-acting opioid should

Withdrawal symptoms may occur following abrupt discontinuation of oxycodone therapy or

Drug abuse studies

Accidental or Intentional Oral Misuse

Special Risk Groups

Use in the elderly

Driving and operating dangerous machinery

INTERACTIONS WITH OTHER MEDICINES

CNS depressants (including sedatives or hypnotics, general anaesthetics, phenothiazines, other

Monoamine Oxidase Inhibitors (MAOIs)

Neuromuscular blocking agents

Opioid agonist analgesics (including morphine, pethidine)

Opioid agonist-antagonist analgesics (including pentazocine, butorphanol, buprenorphine)

Ear and labyrinth disorders

General disorders and administration site conditions

Immune system disorders

Injury, poisoning and procedural complications

Metabolism and nutrition disorders

Nervous system disorders

Renal and urinary disorders

Reproductive system and breast disorders

Respiratory, thoracic and mediastinal disorders

Skin and subcutaneous tissue disorders

Key: Very common (≥ 1/10)

There have been uncommon post-marketing reports of difficulty swallowing OxyContin 10 mg

To avoid difficulty swallowing, OxyContin tablets should not be pre-soaked, licked or

Adults, elderly and children over 12 years

Children under 12 years

Patients with renal or hepatic impairment

Patients transferring from other opioid formulations

Multiplication Factors for Converting the Daily Dose

(mg/Day Prior Opioid x Factor = mg/Day Oral Oxycodone)

Oral Prior Opioid Parenteral Opioid

Treatment of oxycodone overdosage

PRESENTATION AND STORAGE CONDITIONS

Strengths and Pack sizes available in Australia:

Strengths and Pack sizes not available in Australia:

NAME AND ADDRESS OF THE SPONSOR

Further information may be obtained from Mundipharma’s Medical Information Department

POISON SCHEDULE OF THE MEDICINE

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC

DATE OF MOST RECENT AMENDMENT

® OXYCONTIN is a registered trademark.

You might also like